In Brief: Zeneca Diprivan
Zeneca Diprivan: Patent valid until 2015 is granted for reformulation of the I.V. sedative hypnotic to add .005% disodium edetate to retard growth of microorganisms that could result from touch contamination. The patent for propofol without EDTA expired in November 1996. Zeneca received FDA approval to market the EDTA formulation on June 11, 1996 and was granted a three year exclusivity extension in March ("The Pink Sheet" March 24, 1997, T&G-3)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth